Top 5-Cancer Researchers in 2014 Wins Prize
The MD Anderson Cancer Center’s Prize for Cancer Research and American Society of BioMedicine are recognized a new generation of leaders in cancer research, who are making significant contributions to the understanding of cancer or are improving the treatment of the disease through basic or clinical research. The prize is intended to encourage investigators who have a unique opportunity to help shape the future of cancer research. The prize is now awarded to up to five investigators. Recipients are selected by a panel of investigators from leading research institutions. The winners presented their work at a scientific symposium and published through scientific journal.
 |
Breakthrough Prize for cancer immunology research
Jim Allison, MD, PhD, chair of The University of Texas MD Anderson Cancer Center’s Immunology department and executive director of the Moon Shots Program immunotherapy platformAllison discoveries in T cell biology, development of immune checkpoint blockade cancer therapy honored
Basic science research that exposed vital details of cancer’s defense against the immune system, revealing an entirely new way to combat these diseases. |
 |
2014 women in cancer research scholar awards
Diana Azzam, Univ. of Miami – Miller School of Medicine, Miami, FL. Therapeutic targeting of distinct subsets of cancer stem cells within triple-negative breast Cancer Stem Cell Phenotype and Function.Her research focus is to identify small molecule inhibitors that would selectively target the highly metastatic and most aggressive CD24+ subpopulation in triple-negative breast cancers, thus present novel therapeutic avenues for the most deadly type of breast cancers.
|
 |
Cancer cell signaling Prize
Nasser Ghaly Yousif, MD, MSc, PhD Professor Oncology/Hematology, Colorado Univ. Prof. Yousif discovered the main signaling pathway of the ovarian cancer cell metastasis. His results indicate that FAK inhibition can suppress ovarian cancer cells migration and invasion through inhibiting downstream signaling (PI3K/AKT), which might be a therapeutic target or biomarker for ovarian cancer.
|
 |
Cancer Research Scholar Awards
Karen M. Bussard, Wake Forest Univ. School of Medicine, Winston-Salem, NC. Metastatic breast cancer cells induce an osteoblast-TAF-like phenotype and communicate with osteoblasts via gap junctions and exosomal crosstalk to facilitate breast cancer cell quiescence in bone Mini symposium: Stromal Importance in Modulating Tumor Progression.
|
 |
Cancer Research Scholar Awards
Christine Desmedt, Jules Bordet Inst., Brussels. Unraveling breast cancer progression through geographical and temporal sequencing Mini symposium: Molecular Profiling to Elucidate Tumor Heterogeneity and Clonal Evolution.
|